Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

AstraZeneca’s Voydeya approved in the US as add-on therapy for PNH patients with EVH

AstraZeneca's Voydeya (danicopan) has been approved in the US as add-on therapy for PNH patients with EVH. Find out more about this breakthrough treatment...

AstraZeneca Ultomiris granted approval in US for treatment of adults with neuromyelitis optica spectrum disorder

Ultomiris, the first long-acting C5 complement inhibitor, shows promise in reducing relapse risk for AQP4 Ab+ NMOSD patients. Learn more here...

AstraZeneca expands late-stage rare disease pipeline with Amolyt Pharma acquisition

AstraZeneca plc (LON:AZN) has entered an agreement to acquire Amolyt Pharma, focusing on treatments for rare endocrine diseases, including hypoparathyroidism...

GSK announces positive results from DREAMM-8 phase III trial for Blenrep

GSK plc announces positive results from DREAMM-8 trial evaluating Blenrep in combination with PomDex for multiple myeloma treatment. Exciting news for patients and potential treatment advancements...

ConvaTec Group reports accelerating organic revenue growth of 7.2%

ConvaTec Group plc (LON:CTEC) reports strong annual results with 7.2% organic revenue growth, margin expansion and new product launches...

GSK ViiV Healthcare reports Positive Findings for ultra long-acting HIV treatment Cabotegravir

GSK plc's ViiV Healthcare announces positive findings from a phase I study on cabotegravir ultra long-acting for HIV treatment. Exciting progress in long-acting medication development...

AstraZeneca and Daiichi Sankyo’s Dato-DXd validated by EMA for lung and breast cancer treatment

AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) receives EMA validation for lung and breast cancer treatments, advancing the potential for improved patient outcomes...

Haleon delivers strong organic growth of 8%, with Q4 organic growth over 6%

Haleon plc (LON:HLN) presents its full year results for 2023. Join the investor presentation by CEO Brian McNamara and CFO Tobias Hestler on 29th February 2024...

GSK settles another Zantac litigation case

GSK plc has reached a confidential settlement with Boyd/Steenvoord in a California state court case, avoiding a trial set for April 2, 2024...

AstraZeneca’s Voydeya recommended for PNH treatment in EU

AstraZeneca's Voydeya for PNH patients is recommended for EU approval. Learn about this promising treatment and its potential benefits for patients...

ViiV Healthcare announces Superiority of long-acting HIV Therapy over daily oral treatment

ViiV Healthcare announces promising results from LATITUDE phase III trial, showing long-acting HIV treatment Cabenuva's superiority over daily oral therapy...

AstraZeneca’s Tagrisso plus chemotherapy appoved for lung cancer in the US

AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit...

GSK completes acquisition of Aiolos Bio, expanding respiratory biologics portfolio

GSK plc has completed the acquisition of Aiolos Bio, expanding its respiratory biologics portfolio with AIO-001, a potential treatment for asthma patients with low T2 inflammation. The acquisition includes an upfront payment of $1 billion and milestone payments...

GSK receives FDA fast track designation for Bepirovirsen for Chronic Hepatitis B

GSK plc has received Fast Track designation from the FDA for bepirovirsen, an investigational drug for chronic hepatitis B treatment. This designation highlights the need for effective medications to address this serious condition...

AstraZeneca reports Strong Growth and Pipeline Momentum in FY and Q4 2023

AstraZeneca reports strong FY and Q4 2023 results, with revenue growth, new medicine approvals, and optimistic growth projections for 2024...

GSK’s RSV vaccine for adults 50-59 at increased risk accepted by FDA for Priority Review

GSK plc's application to extend its RSV vaccine indication to adults aged 50-59 at risk has been accepted by the FDA for priority review. If approved, it would be the first vaccine for this population. The application is supported by positive phase III trial results...

GSK reaches confidential settlement with David Browne in Zantac case

GSK has reached a confidential settlement with David Browne, resolving a California state court case. The company will continue to defend itself in other Zantac cases...
Search

Funds

Health

AstraZeneca’s Voydeya approved in the US as add-on therapy for PNH patients with EVH

AstraZeneca's Voydeya (danicopan) has been approved in the US as add-on therapy for PNH patients with EVH. Find out more about this breakthrough treatment...

AstraZeneca Ultomiris granted approval in US for treatment of adults with neuromyelitis optica spectrum disorder

Ultomiris, the first long-acting C5 complement inhibitor, shows promise in reducing relapse risk for AQP4 Ab+ NMOSD patients. Learn more here...

AstraZeneca expands late-stage rare disease pipeline with Amolyt Pharma acquisition

AstraZeneca plc (LON:AZN) has entered an agreement to acquire Amolyt Pharma, focusing on treatments for rare endocrine diseases, including hypoparathyroidism...

GSK announces positive results from DREAMM-8 phase III trial for Blenrep

GSK plc announces positive results from DREAMM-8 trial evaluating Blenrep in combination with PomDex for multiple myeloma treatment. Exciting news for patients and potential treatment advancements...

ConvaTec Group reports accelerating organic revenue growth of 7.2%

ConvaTec Group plc (LON:CTEC) reports strong annual results with 7.2% organic revenue growth, margin expansion and new product launches...

GSK ViiV Healthcare reports Positive Findings for ultra long-acting HIV treatment Cabotegravir

GSK plc's ViiV Healthcare announces positive findings from a phase I study on cabotegravir ultra long-acting for HIV treatment. Exciting progress in long-acting medication development...

AstraZeneca and Daiichi Sankyo’s Dato-DXd validated by EMA for lung and breast cancer treatment

AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) receives EMA validation for lung and breast cancer treatments, advancing the potential for improved patient outcomes...

Haleon delivers strong organic growth of 8%, with Q4 organic growth over 6%

Haleon plc (LON:HLN) presents its full year results for 2023. Join the investor presentation by CEO Brian McNamara and CFO Tobias Hestler on 29th February 2024...

GSK settles another Zantac litigation case

GSK plc has reached a confidential settlement with Boyd/Steenvoord in a California state court case, avoiding a trial set for April 2, 2024...

AstraZeneca’s Voydeya recommended for PNH treatment in EU

AstraZeneca's Voydeya for PNH patients is recommended for EU approval. Learn about this promising treatment and its potential benefits for patients...

ViiV Healthcare announces Superiority of long-acting HIV Therapy over daily oral treatment

ViiV Healthcare announces promising results from LATITUDE phase III trial, showing long-acting HIV treatment Cabenuva's superiority over daily oral therapy...

AstraZeneca’s Tagrisso plus chemotherapy appoved for lung cancer in the US

AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit...

GSK completes acquisition of Aiolos Bio, expanding respiratory biologics portfolio

GSK plc has completed the acquisition of Aiolos Bio, expanding its respiratory biologics portfolio with AIO-001, a potential treatment for asthma patients with low T2 inflammation. The acquisition includes an upfront payment of $1 billion and milestone payments...

GSK receives FDA fast track designation for Bepirovirsen for Chronic Hepatitis B

GSK plc has received Fast Track designation from the FDA for bepirovirsen, an investigational drug for chronic hepatitis B treatment. This designation highlights the need for effective medications to address this serious condition...

AstraZeneca reports Strong Growth and Pipeline Momentum in FY and Q4 2023

AstraZeneca reports strong FY and Q4 2023 results, with revenue growth, new medicine approvals, and optimistic growth projections for 2024...

GSK’s RSV vaccine for adults 50-59 at increased risk accepted by FDA for Priority Review

GSK plc's application to extend its RSV vaccine indication to adults aged 50-59 at risk has been accepted by the FDA for priority review. If approved, it would be the first vaccine for this population. The application is supported by positive phase III trial results...

GSK reaches confidential settlement with David Browne in Zantac case

GSK has reached a confidential settlement with David Browne, resolving a California state court case. The company will continue to defend itself in other Zantac cases...
Search

Funds

Health

FTSE 100

Funds